Novavax, Inc. Stock price

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.78 USD -1.44% Intraday chart for Novavax, Inc. +1.27% -0.42%
Sales 2024 * 850M Sales 2025 * 929M Capitalization 669M
Net income 2024 * -90M Net income 2025 * - EV / Sales 2024 * 0.19 x
Net cash position 2024 * 510M Net cash position 2025 * 482M EV / Sales 2025 * 0.2 x
P/E ratio 2024 *
-6 x
P/E ratio 2025 *
46.8 x
Employees 1,543
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.33%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.44%
1 week+1.27%
Current month-3.24%
1 month+8.39%
3 months-2.65%
6 months-33.24%
Current year-0.42%
More quotes
1 week
4.66
Extreme 4.66
4.95
1 month
4.63
Extreme 4.63
6.00
Current year
3.53
Extreme 3.5324
6.05
1 year
3.53
Extreme 3.5324
11.36
3 years
3.53
Extreme 3.5324
277.80
5 years
3.53
Extreme 3.5324
331.68
10 years
3.53
Extreme 3.5324
331.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 23-01-22
President 64 14-03-09
Director of Finance/CFO 58 21-08-15
Members of the board TitleAgeSince
Director/Board Member 57 22-10-28
Director/Board Member 58 20-10-31
Director/Board Member 58 20-06-15
More insiders
Date Price Change Volume
24-03-28 4.78 -1.44% 3,616,355
24-03-27 4.85 +2.97% 3,836,391
24-03-26 4.71 -2.08% 5,216,895
24-03-25 4.81 +2.34% 3,588,092
24-03-22 4.7 -0.42% 2,803,893

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.78 USD
Average target price
15.4 USD
Spread / Average Target
+222.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Novavax, Inc. - Nasdaq